Obesity Management in Modern Indian Clinical Practice

Obesity has emerged as a major metabolic challenge in India, requiring highly tailored clinical interventions. Clinicians frequently encounter patients seeking guidance on choosing between a minimally invasive procedure and a long-term pharmacological regimen. To address this clinical dilemma, researchers at the Asian Institute of Gastroenterology in Hyderabad conducted a comparative analysis. This real-world study evaluated the efficacy of Endoscopic Sleeve Gastroplasty (ESG) against oral semaglutide over twelve months. Consequently, these findings provide invaluable, region-specific evidence for Indian gastroenterologists and endocrinologists. Obesity in India often presents at lower body mass index thresholds than in Western countries. Therefore, indigenous clinical data is essential to optimize patient selection and treatment timelines. In this clinical context, the AIG study serves as a critical guide. It helps medical professionals understand the distinct physiological mechanisms and therapeutic trajectories of both modalities. Ultimately, this trial empowers healthcare providers to design personalized weight management strategies that align with specific patient goals and metabolic profiles. This structured approach ensures that both procedural and pharmaceutical methods are applied where they can deliver the greatest clinical utility. Specifically, clinicians must carefully evaluate individual cardiovascular risk factors and patient compliance before recommending any weight loss pathway.

Endoscopic Sleeve Gastroplasty Efficacy and Outcomes

The AIG retrospective study analyzed 150 adult patients with obesity treated between January 2024 and April 2025. Among these, 50 patients underwent Endoscopic Sleeve Gastroplasty, while 100 received daily oral semaglutide (14 mg) alongside standard lifestyle modifications. Furthermore, the short-term results at six months demonstrated a clear therapeutic advantage for the procedural intervention. Specifically, patients who underwent the endoscopic procedure achieved an average total body weight loss of 12.72%. In contrast, patients in the oral semaglutide group achieved an average weight loss of 8.67%. Additionally, approximately 70% of the procedural patients lost at least 10% of their body weight. Conversely, only 43% of the medication group achieved the same weight loss threshold. Moreover, a striking 36% of the procedural cohort achieved more than 15% weight loss. In comparison, only 7% of those taking the daily tablet met this mark. Thus, for patients requiring rapid weight loss, the endoscopic approach offers a highly effective clinical solution. These robust statistics support the use of endoscopic therapies for patients needing a powerful initial intervention. Medical practitioners can confidently utilize these robust clinical statistics when discussing realistic short-term expectations with their patients.

Long-Term Metabolic Adaptation and Weight Convergence

Although the six-month data heavily favored the procedural approach, the twelve-month outcomes revealed a fascinating metabolic convergence. By the end of one year, the weight loss differences between the two patient cohorts narrowed substantially. Specifically, the endoscopic cohort maintained an average weight loss of 11.92%, whereas the oral semaglutide group reached 10.91%. This narrowing gap demonstrates that pharmacotherapy, while slower to take effect, catches up over time through hormonal mechanisms. Oral semaglutide works through glucagon-like peptide-1 receptor pathways to slowly modify systemic metabolism and consistently reduce long-term appetite. On the other hand, the endoscopic procedure physically restricts the gastric volume, which triggers an immediate drop in caloric intake. However, metabolic adaptation can lead to minor weight fluctuations over an extended timeline. Therefore, both approaches ultimately achieve comparable efficacy after a year. Consequently, long-term success with both treatments depends heavily on continuous behavioural changes, physical activity, and dietary discipline. Clinicians should emphasize that these interventions act as powerful metabolic bridges rather than standalone long-term cures. Furthermore, patients must receive ongoing nutritional guidance to prevent weight regain once the initial metabolic adaptation stabilizes. This collaborative clinical approach remains the most reliable strategy for achieving durable results.

The Mechanism and Cost-Effectiveness of Endoscopic Sleeve Gastroplasty

The endoscopic procedure represents a non-surgical, minimally invasive technique performed under sedation through the mouth using a standard endoscope. During this forty-five-minute procedure, physicians place durable medical sutures inside the stomach to reduce its functional capacity. Consequently, patients experience early satiety and reduced hunger without undergoing external incisions or permanent gastric tissue removal. On the other hand, oral pharmacotherapy involves a daily tablet that requires long-term compliance under strict medical supervision. Furthermore, comparing the financial implications of these two approaches is essential for Indian patients. While the endoscopic procedure demands an upfront cost of approximately Rs 1.5 lakh, it is a one-time expense. Conversely, oral semaglutide is initially cheaper but requires indefinite, long-term monthly purchases. Over several years, the cumulative cost of daily medication becomes comparable to the cost of the endoscopic procedure. Therefore, clinicians must guide patients through this comprehensive cost-benefit analysis. This process helps them identify a pathway that is both clinically suitable and financially sustainable. This financial aspect remains a primary consideration in our healthcare ecosystem. By evaluating both immediate financial layouts and long-term treatment adherence, patients can make highly informed decisions. Ultimately, this approach leads to improved satisfaction and better overall compliance with the chosen metabolic therapy.

Patient Selection and Clinical Applications

Identifying the right candidate for each treatment modality is key to achieving optimal clinical success in obesity management. According to the study findings, the rapid weight loss produced by the endoscopic procedure is highly beneficial for specific clinical situations. For example, patients who require urgent weight reduction prior to major orthopedic surgeries are ideal candidates. Likewise, individuals preparing for high-risk cardiac interventions benefit significantly from rapid pre-operative weight loss to minimize surgical risks. In contrast, oral semaglutide is suitable for patients preferring a non-procedural approach. However, these individuals must remain comfortable with a daily, long-term medication schedule. Furthermore, clinicians must carefully monitor these patients for potential gastrointestinal side effects, such as nausea or abdominal discomfort. Therefore, medical professionals must individualize obesity management based on patient goals, comorbidities, and compliance potential. Neither intervention should ever replace the foundational pillars of proper nutrition and regular physical exercise. By utilizing these therapies as strategic bridges, clinicians can help patients achieve sustainable metabolic health. Additionally, consistent follow-up visits with a dedicated multidisciplinary care team are vital for tracking metabolic progress. This collaborative oversight ensures that patients maintain their weight reduction achievements long after the initial intervention phase.

Frequently Asked Questions

Q1: What is the main difference in weight loss outcomes between Endoscopic Sleeve Gastroplasty and oral semaglutide in the first six months?

The study demonstrated that Endoscopic Sleeve Gastroplasty achieves significantly faster short-term weight loss. At six months, patients who underwent the procedure achieved an average body weight loss of 12.72%. In contrast, patients taking oral semaglutide 14 mg achieved 8.67%. Additionally, 70% of the procedural patients lost at least 10% of their body weight, proving the procedure offers a stronger initial metabolic impact.

Q2: Why does the difference in weight loss between the two groups narrow after twelve months?

The weight loss gap narrows because both modalities operate through different pathways. The endoscopic procedure reduces stomach size physically, producing immediate restrictive effects. Conversely, oral semaglutide works through hormonal mechanisms that alter appetite. Consequently, patients taking the tablet catch up, achieving a comparable average weight loss of 10.91% compared to 11.92% in the procedural group at the twelve-month milestone.

Q3: Which patient profiles are best suited for Endoscopic Sleeve Gastroplasty?

The rapid weight loss achieved through Endoscopic Sleeve Gastroplasty makes it suitable for patients requiring immediate metabolic improvements. Specifically, individuals preparing for major cardiac or orthopedic surgeries benefit from rapid reduction to minimize surgical complications. Additionally, the procedure is ideal for patients struggling with daily pharmaceutical compliance. However, neither approach succeeds without lifelong behavioral adjustments and dietary discipline under proper medical guidance.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. ESG helps faster short-term weight loss than oral meds: AIG study - ETHealthworld


2. Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Cohort Study - Endoscopy